Fig. 6.
High expression of RasGRP4 was associated with tumor size and poor prognosis in DLBCL patients. (a) The expression level of RasGRP4 was significantly higher in DLBCL patients with the largest lesion diameter of ≥10 cm (P = 0.0004). (b) RasGRP4 expression was significantly higher in patients with a high-risk IPI (or aaIPI) score (P = 0.0042). (c) RasGRP4 expression was significantly different when the number of extranodal organs involved was greater than 2 (P = 0.0108). (d) The expression of RasGRP4 was positively correlated with SUVmax value in patients with DLBCL (P < 0.001). N indicates the number of independent experiments. **P < 0.01, *P < 0.05